GNPX Genprex, Inc.

Nasdaq genprex.com


$ 4.43 $ 0.29 (7 %)    

Friday, 14-Nov-2025 15:53:36 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 4.43
$ 4.07
$ 4.41 x 214
$ 4.50 x 118
$ 4.00 - $ 4.47
$ 3.90 - $ 84.50
207,531
na
10.06M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-21-2023 06-30-2023 10-Q
11 05-22-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-30-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-26-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-13-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 04-17-2018 12-31-2017 10-K
33 11-27-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genprex-announces-10m-atm-registered-direct-offering-of-377780-shares-of-common-stock-at-900-per-share

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on dev...

 genprex-said-the-combination-of-reqorsa-gene-therapy-quaratusugene-ozeplasmid-and-an-alk-inhibitor-led-to-longer-survival-in-the-mouse-model-of-alk-eml4-positive-non-small-cell-lung-cancer

Reqorsa Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerCombining REQORSA wi...

 genprex-to-present-positive-preclinical-data-at-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics-in-boston

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on dev...

 genprex-implements-previously-disclosed-1-for-50-reverse-stock-split-reducing-outstanding-shares-to-1004326

As of 12:01 a.m. on October 21, 2025, Genprex, Inc., a Delaware corporation (the "Company"), effected the previously di...

 genprex-gnpx-shares-jump-41-after-hours-following-new-cancer-therapy-data

Genprex shares jumped 41% in after-hours trading following news of a key cancer therapy presentation and ongoing research colla...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION